The pharmaceutical industry trade group hopes to convince you that it is not all bark and no bite.
In response to the outcry over Marathon Pharmaceuticals, which plans to sell a decades-old drug for $89,000 and also maintain a monopoly, the Pharmaceutical Research and Manufacturers of America slammed the company for “actions [that] are not consistent with the mission of our organization.” And the group promised a “comprehensive review” of its membership criteria.
The goal is to “ensure we are focused on representing research-based biopharmaceutical companies who take significant risks to bring new treatments and cures to patients,” according to a statement from the trade group. PhRMA, by the way, has not bothered to publicly post this declaration of intent on its web site, but instead, only distributed it to those who asked for its official views on Marathon.
About the Author Reprints
What a joke. Cat calling the kettle black.